Search

Approximately 4,500 children and teens are diagnosed with leukemia in the United States and Canada each year. The illness and its treatment can have a devastating effect on family, friends, classmates, and the larger community. This newly updated edition of Childhood Leukemia contains the information and support parents need during this difficult time, including:New treatments such as immunotherapy, tailoring drugs dosages to children's genetic profiles, and ways to deal with side effects.Advice on how to cope with procedures, hospitalization, school, family, and financial issues.Tips for forming a partnership with the medical team.Poignant and practical stories from family members.Updated resources for medical information, emotional support, and financial assistance.Parents who read this book will find understandable medical information and emotional support.

Discusses the history and science of leukemia, its causes and current treatments.

The world of experimental leukemia research is a miniature of cancer research. Cancer research started from experimental leukemia/sarcoma research of Ellermann and Bang and Peyton Rous in early 1900s. Experimental leukemia includes most of important elements of cancer research; both viral and chemical carcinogenesis; most of important oncogenes and suppressor genes and the related cell biology. The author has added only a few sections such as skin carcinogenesis done by Yamagiwa and Berenblum and DNA viruses from outside of experimental leukemia. By doing this, this book covers most of important topics of modern oncology, except researches done on human cancers. In this book, the author has arranged the chapters to contrast the pioneer works by Peyton Rous, Jacob Furth, and Ludwik Gross, etc, done more than half a century ago and the recent works by molecular biologists. Although the former pathologists provided various experimental materials, faced to severe criticism by contemporary researchers and they had tough hearts to cope with them, molecular biologists solved questions on these materials step by step by disclosing the invisible molecular events as a visible charts, molecular diagrams, or 3-D models just as magicians do. Experimental leukemia has always afforded the key materials for solution of cancer. In experimental leukemia, mutations and genetic recombination play an important role. They include ras gene mutations, insertional mutagenesis and gene transduction by retroviruses, recombination among retroviruses, and chromosome translocations. Most of them occur in highly specific genomic sites. However, the reason for the specificity in target sites remained obscure. The author was especially interested in the common target genomic sites for chemical carcinogens and retroviruses. Therefore the common pathway for retroviruses and chemicals became one of the main topics of this book.

Meeting the needs for haematologists and clinical chemists for an up to date reference, this atlas provides a visual presentation of lymphoproliferative disorders, leukaemia and plasma cell neoplasms. Compiled by leading experts in the UK, each malignancy is surveyed based on molecular and cellular changes, including histochemistry, cytochemistry and relevant radiographs. Pertinent clinical information relating to clinical presentation, differential diagnosis and prognostic indicators are concisely outlined, using numerous graphics and citing key references in the field. A companion volume in.

Divided into three parts, this atlas of hematologic oncology presents a modern approach to the differential diagnosis of important blood cancers. The introduction explains specific terms, morphologic and phenotype features, and normal morphology. The book follows a systematic approach, illustrating hematolymphoid neoplasms based on the current WHO classification, with emphasis on most valuable and typical diagnostic features. The differential diagnoses focus on clinical presentation, histologic pattern, and phenotype. This approach simplifies the complexity of the classification and diagnosis of hematolymphoid malignancies.